1.87
전일 마감가:
$1.84
열려 있는:
$1.79
하루 거래량:
4.89M
Relative Volume:
2.10
시가총액:
$392.09M
수익:
$95,000
순이익/손실:
$-327.27M
주가수익비율:
-0.7633
EPS:
-2.45
순현금흐름:
$-239.25M
1주 성능:
-1.06%
1개월 성능:
-8.78%
6개월 성능:
-23.36%
1년 성능:
-32.73%
Allogene Therapeutics Inc Stock (ALLO) Company Profile
명칭
Allogene Therapeutics Inc
전화
(650) 457-2700
주소
210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
ALLO을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
ALLO
Allogene Therapeutics Inc
|
1.87 | 392.09M | 95,000 | -327.27M | -239.25M | -2.12 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
![]()
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
![]()
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Allogene Therapeutics Inc Stock (ALLO) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2024-08-08 | 재개 | Oppenheimer | Outperform |
2024-05-31 | 개시 | Piper Sandler | Overweight |
2024-01-05 | 다운그레이드 | Guggenheim | Buy → Neutral |
2024-01-05 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
2023-12-08 | 개시 | Citigroup | Buy |
2023-06-26 | 재개 | Oppenheimer | Outperform |
2023-03-21 | 개시 | Bernstein | Mkt Perform |
2023-01-24 | 업그레이드 | JP Morgan | Neutral → Overweight |
2023-01-06 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
2022-12-12 | 다운그레이드 | BofA Securities | Buy → Underperform |
2022-08-10 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
2022-07-15 | 업그레이드 | Goldman | Neutral → Buy |
2022-06-03 | 개시 | Robert W. Baird | Neutral |
2022-02-28 | 재확인 | B. Riley Securities | Buy |
2021-10-20 | 개시 | Cowen | Outperform |
2021-10-08 | 다운그레이드 | Goldman | Buy → Neutral |
2021-10-08 | 다운그레이드 | Stifel | Buy → Hold |
2021-09-23 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
2021-06-21 | 재개 | Jefferies | Buy |
2021-05-20 | 업그레이드 | Truist | Hold → Buy |
2021-05-14 | 개시 | B. Riley Securities | Buy |
2021-01-26 | 업그레이드 | Stifel | Hold → Buy |
2020-12-10 | 재개 | H.C. Wainwright | Buy |
2020-11-24 | 개시 | BofA Securities | Buy |
2020-10-23 | 개시 | RBC Capital Mkts | Outperform |
2020-06-01 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
2020-05-29 | 재확인 | H.C. Wainwright | Buy |
2020-05-19 | 업그레이드 | ROTH Capital | Neutral → Buy |
2020-05-15 | 업그레이드 | Guggenheim | Neutral → Buy |
2020-05-14 | 재확인 | H.C. Wainwright | Buy |
2020-05-14 | 다운그레이드 | SunTrust | Buy → Hold |
2020-04-13 | 개시 | SunTrust | Buy |
2020-03-13 | 개시 | H.C. Wainwright | Buy |
2020-03-05 | 개시 | Stifel | Hold |
2020-02-24 | 개시 | Berenberg | Hold |
2019-12-18 | 개시 | JMP Securities | Mkt Outperform |
2019-11-04 | 개시 | Canaccord Genuity | Buy |
2019-08-09 | 개시 | BTIG Research | Buy |
2019-06-05 | 개시 | ROTH Capital | Neutral |
2019-05-31 | 개시 | Guggenheim | Neutral |
2019-05-23 | 개시 | Stifel | Hold |
2019-03-29 | 개시 | Piper Jaffray | Overweight |
모두보기
Allogene Therapeutics Inc 주식(ALLO)의 최신 뉴스
Allogene Therapeutics (ALLO) Stock Drops Amid Biotech Sector Dec - GuruFocus.com
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Allogene Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Allogene Therapeutics CEO to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Short Interest Update - MarketBeat
Allogene stock hits 52-week low at $1.98 amid market challenges - Investing.com Canada
Allogene stock hits 52-week low at $1.98 amid market challenges By Investing.com - Investing.com South Africa
Allogene Therapeutics' SWOT analysis: CAR T pioneer's stock faces pivotal phase - Investing.com
Allogene Therapeutics (ALLO) Stock Drops Amidst Biotech Sector D - GuruFocus.com
Allogene Therapeutics Acknowledges the Passing of Founding Board Member David Bonderman - The Manila Times
Allogeneic T Cell Therapies Market Report, 2024-2028 & 2033 - GlobeNewswire
Allogene Therapeutics Mourns Loss of Founding Board Member David Bonderman, Pioneer in CAR T-cell Innovation - StockTitan
Allogene Therapeutics, Inc. Acknowledges the Passing of Founding Board Member David Bonderman - Marketscreener.com
Insider Sell: Deborah Messemer Sells 9,136 Shares of Allogene Th - GuruFocus.com
Allogene Therapeutics: Showing Promise Despite Some Shaky Safety (NASDAQ:ALLO) - Seeking Alpha
Zacks Investment Management Purchases New Position in Allogene Therapeutics, Inc. (NASDAQ:ALLO) - MarketBeat
Allogene Therapeutics (ALLO) Stock Surges Amid Positive Analyst Ratings - GuruFocus.com
Fmr LLC Reduces Holdings in Allogene Therapeutics, Inc. (NASDAQ:ALLO) - MarketBeat
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Sees Large Decrease in Short Interest - MarketBeat
Allogene Therapeutics Loses 23% Year to Date: How to Play the Stock? - MSN
Allogene Therapeutics Loses 23% Year To Date: How To Play The Stock? - Barchart
Vestal Point Capital LP Trims Position in Allogene Therapeutics, Inc. (NASDAQ:ALLO) - MarketBeat
Allogene’s ALLO-329 shows efficacy at killing CD19- and CD70-expressing cells - BioWorld Online
Allogene Therapeutics (ALLO) Upgraded to Buy: Here's Why - Yahoo Finance
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
ALLO (Allogene Therapeutics) Investments And Advances : $111.82 Mil (As of Sep. 2024) - GuruFocus.com
Is Allogene Therapeutics (NASDAQ:ALLO) In A Good Position To Invest In Growth? - Simply Wall St
Allogene stock touches 52-week low at $2 amid market challenges - Investing.com India
Allogene's Q3 Loss Narrower Than Expected, Sales Nil - MSN
ALLOAllogene Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Allogene Therapeutics Announces Participation in December Investor Conferences - The Manila Times
Allogene Therapeutics to Present at Three Major Healthcare Conferences | ALLO Stock News - StockTitan
Allogene Therapeutics Presents Preclinical Data for ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Disease at the American College of Rheumatology (ACR) Convergence - The Manila Times
Allogene Therapeutics Presents Preclinical Data for - GlobeNewswire
Allogene's Novel Dual CAR T ALLO-329 Shows Promise in Autoimmune Disease Study | ALLO Stock News - StockTitan
Allogene Therapeutics, Inc Decides to Discontinue Enrollment in Its Phase 1 Cohort in the ALPHA2 Clinical Trial to Evaluate cemacabtagene ansegedleucel - Marketscreener.com
Short Interest in Allogene Therapeutics, Inc. (NASDAQ:ALLO) Declines By 5.8% - MarketBeat
Allogene halts enrollment in leukemia trial By Investing.com - Investing.com Australia
Allogene’s CAR-T ALLO-316 Demonstrates Ability to Produce Responses in Renal Cell Carcinoma, but Safety Data Includes 3 On-Study Deaths - CGTLive™
Allogene halts enrollment in leukemia trial - Investing.com
Allogene Therapeutics (NASDAQ:ALLO) Shares Down 6.3% on Analyst Downgrade - MarketBeat
Allogene Bows to BMS in Leukemia, Ending Phase I CAR T Enrollment - BioSpace
Piper Sandler Cuts Allogene Therapeutics (NASDAQ:ALLO) Price Target to $9.00 - MarketBeat
Allogene shares target cut, rating held on trial enrollment issue By Investing.com - Investing.com UK
Q3 Biotech Earnings Recap: Nkarta, Intellia, Cassava and more - BioSpace
Allogene Therapeutics's SWOT analysis: CAR-T pioneer's stock faces pivotal year - Investing.com India
Allogene Therapeutics Inc (ALLO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Allogene Therapeutics Inc 주식 (ALLO) 내부자 거래
내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
---|---|---|---|---|---|---|---|
Humer Franz B | Director |
Dec 05 '24 |
Sale |
2.16 |
9,221 |
19,917 |
307,507 |
자본화:
|
볼륨(24시간):